SCHEMBL25554268

SCHEMBL25554268

Cc1ccc(CCOc2ccc3[nH]cc(NC(=O)C4CCC4)c3c2)cn1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AAK1 Q2M2I8 2/20 0.44
STK17B O94768 1/20 0.44
PIM1 P11309 1/20 0.43
PIM2 Q9P1W9 1/20 0.43
MTNR1A P48039 6/20 0.42
MTNR1B P49286 6/20 0.42
ALDH1A1 P00352 2/20 0.41
FFAR4 Q5NUL3 1/20 0.40
P2RX3 P56373 2/20 0.40
EGFR P00533 1/20 0.39
IGF1R P08069 1/20 0.39
FLT4 P35916 1/20 0.39
KDR P35968 1/20 0.39
F10 P00742 1/20 0.38
ABL1 P00519 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
HTT P42858 1/20 0.38
POLB P06746 1/20 0.37
KDM4E B2RXH2 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30233558 0.88 AAK1 (0.40) AAK1STK17BPIM1PIM2MTNR1A
SCHEMBL25024418 0.88 AAK1 (0.40) AAK1STK17BPIM1PIM2MTNR1A
SCHEMBL25554263 0.87 MTNR1A (0.50) MTNR1AMTNR1BALDH1A1P2RX3EGFR
SCHEMBL25554539 0.86 MTNR1A (0.47) AAK1PIM1PIM2MTNR1AMTNR1B
SCHEMBL25552561 0.84 MEN1 (0.45) MTNR1AMTNR1BALDH1A1EGFRIGF1R
SCHEMBL25918840 0.81 RXFP1 (0.44) AAK1STK17BMTNR1AMTNR1BF10
SCHEMBL25026120 0.80 MEN1 (0.45) PIM1PIM2MTNR1AMTNR1BF10
SCHEMBL25025570 0.80 F10 (0.44) PIM1PIM2MTNR1AMTNR1BALDH1A1
SCHEMBL25563167 0.79 MTNR1A (0.40) MTNR1AMTNR1BALDH1A1EGFRIGF1R
SCHEMBL25024325 0.79 MTNR1A (0.38) AAK1STK17BPIM1PIM2MTNR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230167057-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY NOVARTIS PHARMA AG (CH) 2023-06-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230167057-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY STING1, CGAS, IRF3 AAK1 1490/4885STK17B 1507/4885PIM1 2978/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.